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Executive summary
Background
Chlamydia is the most common sexually-
transmitted infection in the world. Left untreated, 
chlamydia can cause epididymitis and urethritis 
in men, and cervicitis and urethritis in women, 
as well as potentially creating future fertility 
problems for women (e.g. ectopic pregnancy, pelvic 
inflammatory disease and tubal infertility). Yet, 
50% of infected men and 70% of infected women 
do not experience symptoms of the infection.
Throughout the UK, testing for chlamydia involves 
the use of nucleic acid amplification tests (NAATs). 
These tests are very accurate, but are laboratory 
dependent, creating a delay between testing and 
receipt of diagnosis, caused by the time it takes 
to transport the test sample to the laboratory and 
process the result. This delay is problematic, as 
a number of infected patients will not return for 
treatment, following their positive diagnosis.
Point-of-care testing methods can provide results 
within hours after the tests are carried out, 
which could allow infected patients to be treated 
immediately, as well as allowing the immediate 
identification of recent sexual partners who should 
also be tested. Currently, point-of-care methods 
are not recommended for use in the NHS because 
they are less accurate than methods used in current 
practice, but if new point-of-care tests reported 
improved accuracy or increased the uptake of 
testing, they could potentially become an effective 
alternative to laboratory testing. The Chlamydia 
Rapid Test (CRT) is a point-of-care test that has 
reported improved accuracy.
Objectives
The objective of this review was to assess whether 
or not the CRT could improve detection of genital 
chlamydia, and whether it is more effective than 
current practice using NAATs, in terms of the 
number of cases of chlamydia that are detected and 
treated, and the proportion of partners identified 
and treated.
This review also sought to establish the incremental 
cost-effectiveness of the CRT (compared with 
current practice), and patients’ own preferences for 
chlamydia testing services.
Methods
Electronic searches were undertaken to identify 
published and unpublished reports. Electronic 
databases searched included MEDLINE, EMBASE, 
BIOSIS and CENTRAL. The most recent search 
was conducted in November 2008. The types of 
studies considered were randomised controlled 
trials (RCTs) for the reviews of diagnostic accuracy 
and effectiveness, direct head-to-head studies 
for the review of diagnostic accuracy, and non-
randomised comparative studies if there was an 
insufficient number of RCTs identified for the 
review of effectiveness. Participants were sexually 
active adolescent and adult women and men, 
suspected of having or being tested for genital 
chlamydia infection. The tests considered were 
the CRT and other comparator point-of-care tests 
identified, using a NAAT as a reference standard.
One reviewer screened the titles and abstracts 
of all reports identified by the search strategy. 
Two reviewers independently assessed all full-
text reports of potentially relevant studies. One 
reviewer extracted data from the included full-text 
studies, which were checked by the second reviewer. 
For the diagnostic accuracy review, two reviewers 
independently assessed the quality of all included 
studies using a modified version of the QUADAS 
(Quality Assessment of Diagnostic Accuracy 
Studies) instrument. For the effectiveness review, 
modified checklists adapted from Verhagen and 
colleagues (1998) were to be used for RCTs and 
non-randomised studies.
The results of the individual studies were tabulated, 
and sensitivity, specificity, positive and negative 
likelihood ratios, and diagnostic odds ratios 
(DORs) calculated. Hierarchical summary receiver 
operating characteristic (HSROC) curves were 
produced for each test where sufficient data for 
analysis were reported. Meta-analysis models were 
fitted using HSROC models. Summary sensitivity, 
specificity, positive and negative likelihood ratios, 
and DORs for each model were reported as a 
median and a 95% confidence interval (CI). For Health Technology Assessment 2010; Vol. 14: No. 29 (Executive summary)
studies reporting effectiveness outcomes, meta-
analysis was to be used to estimate a summary 
measure of effect, with dichotomous outcome data 
combined using relative risk using a fixed effect 
model in the absence of statistical heterogeneity.
A review of the preferences of patients was also 
conducted and was confined to studies that had 
reported willingness to pay or reported preferences 
between different relevant screening test regimens. 
Only economic measures of preference based on 
population values were considered, as such data 
would be most useful for priority setting. Only 
two studies were identified. A discrete choice 
experiment suggested that family planning clinics 
were preferred as a facility for screening, and less 
invasive techniques were favoured.
For cost-effectiveness analysis, a simple decision 
model was used to show that patients attend 
different screening facilities and are faced with 
the choice of accepting or not accepting the 
test offer and providing the sample for the test. 
Most who attend accept the offer, and a small 
proportion of those who do attend would not be 
able to provide the sample required and remain 
unscreened. The prevalence rate has been used to 
determine the proportion of those tested who are 
expected to have chlamydia. The sensitivity and 
specificity of the tests that are being compared 
identify the proportion of the patients correctly or 
incorrectly identified in the model. It is assumed 
that a significant proportion of positive cases 
and their partners are treated. Effectiveness was 
measured in terms of the absolute numbers of true-
positives, false-positives, false-negatives (and other 
positive cases missed) and true-negatives detected. 
Costs were considered from the health service’s 
perspective. Incremental cost-effectiveness ratios 
were used to examine the relative cost-effectiveness, 
and values of the major parameters of the models 
were varied in a sensitivity analysis.
Results
Thirteen studies enrolling 8817 participants were 
included in the analysis. In the pooled estimates 
for the CRT, two studies compared five separate 
sets of vaginal swab specimens, and a further two 
studies compared four sets of first void urine (FVU) 
specimens. The sensitivity (95% CI) of the CRT was 
80% (73% to 85%) for vaginal swab specimens and 
77% (59% to 89%) for FVU specimens. Specificity 
was 99% (99% to 100%) for vaginal swab specimens 
and 99% (98% to 99%) for FVU specimens.
In the pooled estimates for a comparator point-
of-care test (Clearview Chlamydia), four studies 
compared eight separate sets of vaginal, cervical 
and urethral specimens. For cervical specimens 
alone, there were four sets of specimens from the 
four studies. The sensitivity (95% CI) was 52% (39% 
to 65%) for vaginal, cervical and urethral swab 
specimens combined, and 64% (47% to 77%) for 
cervical specimens alone. Specificity was 97% (94% 
to 100%) for vaginal, cervical and urethral swab 
specimens combined, and 97% (88% to 99%) for 
cervical specimens alone.
No studies were identified comparing non-
diagnostic clinical effectiveness outcomes for point-
of-care tests compared with NAATs, for example 
the number of cases detected and treated, and the 
number of partners contacted and treated.
The results of the economic evaluation showed that 
for a hypothetical cohort of 1000 people, using 
the current practice of polymerase chain reaction 
testing would result in 12.63 people who were 
offered testing being correctly treated and having 
their sexual partners contacted, at a cost of £7070 
(for the whole cohort). For the CRT, the number 
being correctly treated would be 10.98, at a cost 
of £7180. For the Clearview Chlamydia test, the 
number correctly treated would be 7.14, at a cost of 
£7170. Both point-of-care tests were therefore more 
costly and less effective than current practice.
An increase in uptake rates, improvement in 
diagnostic performance and reductions in cost 
would all potentially make the CRT worthwhile, 
but it is unclear whether changes of sufficient 
magnitude are feasible.
Patient preferences indicated that those being 
tested preferred for treatment to be provided in 
a family planning clinic setting, preferred less 
invasive methods of specimen collection (e.g. FVU), 
and preferred having a trained health-care advisor 
present for support. If services accommodate these 
preferences as far as possible, there is potentially 
an opportunity to increase uptake rates for testing.
Discussion
There was insufficient evidence to suggest that the 
CRT could improve detection of genital chlamydia 
infection compared with current practice, as there 
were insufficient comparisons available to allow 
robust conclusions to be drawn from the analysis. 
In addition, as no comparative studies were Executive summary: Rapid point-of-care tests for the detection of genital chlamydia infection
identified reporting non-diagnostic outcomes, it 
was not possible to conduct the review of clinical 
effectiveness to determine whether the CRT 
could detect and treat more people than methods 
currently in use. Current practice was found to 
be less costly and more effective, although there 
were circumstances under which point-of-care 
testing could become a viable alternative (i.e. 
if uptake rates for testing were increased using 
this point-of-care method). Patients’ preferences 
for the provision of chlamydia services favoured 
non-invasive testing methods, provided in a 
family planning setting. Robust evidence on 
patient preferences for point-of-care testing was 
not available, although where reported in the 
diagnostic accuracy studies, participants found 
these tests to be very acceptable.
Conclusions
The limited evidence available suggests that 
NAATs are still the most accurate and cost-effective 
method for diagnosing chlamydia infection. There 
may be circumstances in which point-of-care tests 
could be provided in addition to existing NAAT 
services (e.g. where this might increase uptake rates 
or reduce non-return rates for treatment), but there 
is currently little evidence on point-of-care methods 
in such settings. Research on this would be useful, 
along with research on the acceptability of point-
of-care testing. Robust evidence of the diagnostic 
accuracy of point-of-care tests for different types 
of samples is also still required, as are studies 
comparing clinical effectiveness outcomes for these 
tests in comparison with NAATs.
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